Global Cancer Biomarkers Market 2023 Insights And Statistics: Industry Size Till 2030

Market Overview:

The Cancer Biomarkers Market size is anticipated to reach USD 48.52 billion by 2028 from an estimated USD 16.56 billion in 2021, growing at a CAGR of 16.6% globally. Analysis Period 2023 - 2030.

Biomarker testing involves the examination of genes, proteins, and other substances, known as biomarkers or tumor markers, to gather cancer information. Each individual's cancer exhibits a distinct pattern of biomarkers. Biomarkers, which are also referred to as molecular markers or signature molecules, are biological substances found in body tissues, blood, and other bodily fluids. They function as indicators of normal or abnormal processes, as well as various diseases and conditions, as stated by the National Cancer Institute (NCI). These biomarkers can encompass RNA, DNA, proteins, or metabolomics profiles that are specific to tumors.

Key Players For The Global Cancer Biomarkers Market

BioMérieux Inc. (France), INOVIQ (Australia), Bio-Rad Laboratories Inc. (California), Abbott (US), Becton, Dickinson, and Company (US), Merck KgaA (Germany), QIAGEN (Germany), Thermo Fisher Scientific Inc. (US), CENTOGENE N.V. (Germany), PerkinElmer Inc. (US), Siemens Healthcare Private Limited (Germany), and other major players.

Acquire PDF Sample Report + All Related thorough TOC, Graphs and Tables of Global Cancer Biomarkers Market Now:

https://introspectivemarketresearch.com/request/16460

Market Dynamics:

Driver:

The growing prevalence of cancer can be attributed to various factors. The aging population plays a significant role. As people live longer, the risk of developing cancer increases, as cancer is primarily a disease of aging. With improved healthcare and life expectancy, more individuals are reaching an age where they are susceptible to cancer. Lifestyle factors contribute to the rise in cancer cases. Unhealthy behaviors such as tobacco and alcohol use, poor diet, sedentary lifestyle, and exposure to environmental pollutants and radiation have been linked to an increased risk of cancer. As these behaviors become more prevalent, so does the incidence of cancer. Environmental factors play a role as well.

Opportunities:

Technological advancements have led to the development of more accurate and efficient diagnostic tools for cancer. Advanced imaging techniques, such as positron emission tomography (PET), magnetic resonance imaging (MRI), and high-resolution ultrasound, allow for earlier and more precise detection of tumors. Additionally, molecular diagnostic tests, including genetic profiling and liquid biopsies, enable the identification of specific biomarkers associated with different cancer types, facilitating personalized treatment approaches. Technological developments have paved the way for precision medicine, which involves tailoring treatment strategies

Read More This Research Report: -

https://introspectivemarketresearch.com/reports/cancer-biomarkers-market/

The Report Will Include A Major Chapter

•Patent Analysis
•Regulatory Framework
•Technology Roadmap
•BCG Matrix
•Heat Map Analysis
•Price Trend Analysis
•Investment Analysis
•Company Profiling and Competitive Positioning
•Industry Value Chain Analysis
•Market Dynamics and Factors
•Porter's Five Forces Analysis
•Pestle Analysis

Moreover, the report includes significant chapters such as Patent Analysis, Regulatory Framework, Technology Roadmap, BCG Matrix, Heat Map Analysis, Price Trend Analysis, and Investment Analysis which help to understand the market direction and movement in the current and upcoming years.

Market Segmentation

By Biomarker Type, protein biomarker is expected to account for the largest market share in the forecasted period. The protein biomarker is used for the early detection of the breast as well as colonic cancer. Breast cancer and colon cancer are the most common type of cancer and major cause of death around the world. According to WHO, around 2.3 million women were diagnosed with breast cancer and 685,000 death occurred due to breast cancer in 2020 worldwide and 1.9 million people were colonic cancer. The growing cases of breast cancer as well as colon cancer, increase the R&D of the protein biomarkers. For instance, the Food and Drug Administration (FDA) approved the protein biomarkers which contain carcinoembryonic antigen (CEA) in colon cancer, cancer antigen 125 (CA125) in ovarian cancer, and prostate-specific antigen (PSA) in prostate cancer. Thus, the protein biomarkers have maximum growth in the cancer biomarkers market.

By Cancer Type, breast cancer is projected to have the maximum market share in the cancer biomarker market during the analysis period. Breast cancer is one of the most common cancers in women. Breast cancer occurs due to various reasons such as genetic mutation, being overweight, reproductive history, and alcohol drinking. The risk of breast cancer increases the age. In 2020, there were 55% of women aged 65 years old or over. Protein biomarkers are the choice for the treatment of breast cancer. Thus, the growing incidence of breast cancer among women which is the rising demand for biomarkers for treatment propels the growth of the cancer biomarkers market.

By Cancer Biomarkers:

•Genetic Biomarkers
•Protein Biomarkers
•Other Cancer Biomarkers

By Cancer Type:

•Lung Cancer
•Breast Cancer
•Kidney Cancer
•Liver Cancer
•Others

By End Users:

•Academic & Cancer Research Institutes
•Hospitals
•Cancer Diagnostic Laboratories
•Ambulatory Surgical Centers

Get 50% Discount on This Report:

https://introspectivemarketresearch.com/discount/16460

Introspective Market Research is a globally trusted partner delivering comprehensive market research studies that provide businesses with invaluable insights and strategic guidance, facilitating informed decision-making. Our research approach encompasses an extensive range of primary and secondary sources, ensuring utmost accuracy.
The study offers an in-depth analysis of the Cancer Biomarkers market ecosystem, examining the functions and interdependencies of various market stakeholders. Through our expert utilization of trusted methodologies such as SWOT Analysis, Porter's Five Forces Analysis, and Price Trend Analysis, we provide a comprehensive understanding of the regulatory landscape and prevailing trends.

Regional Analysis Of Cancer Biomarkers Market

North America is the dominant region in the cancer biomarkers market owing to the growing number of cancer patients. The increasing number of tobacco, and alcohol consumption, unhealthy food habits, genetic mutation, hormonal imbalance, growing demand for early diagnosis, and the rising geriatric population in this region. These are the common causes of cancer. For instance, there were 32.51 million Americans smoked cigarettes in the year 2020. Statista stated that in 2020 North America had the highest 12-month rate of the prevalence of cancer. Thus, the incidence of cancer in this region is increased. In the United State, there were236 thousand lung cancer cases diagnosed in 2021. Growing awareness about the treatment of cancer among American people the organizations increasing their investment in research and development of biomarkers for cancer treatment. Growing population with cancer and rising investment in the development of biomarkers people the growth of the cancer biomarkers market in the North American region.

By Region:

•North America (U.S., Canada, Mexico)
•Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
•Western Europe (Germany, U.K., France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
•Asia-Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)
•Middle East & Africa (Turkey, Saudi Arabia, Bahrain, Kuwait, Qatar, UAE, Israel, South Africa)
•South America (Brazil, Argentina, Rest of SA)

Inquire Before Purchase: -

https://introspectivemarketresearch.com/inquiry/16460

Key Industry Development In The Cancer Biomarkers Market

In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), established Elecsys Anti-p53 immunoassay for the diagnosis of various cancer types.

In December 2020, FDA approves the NGS-based companion diagnostic of Thermo Fisher Scientific (US) for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.

Table of Content:

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Cancer Biomarkers Market by Type
Continued…..

For More Related Reports Click Here:

https://introspectivemarketresearch.com/reports/online-exams-proctoring-market/

https://introspectivemarketresearch.com/reports/software-testing-tool-market/

https://introspectivemarketresearch.com/reports/uv-fluorescent-inks-market/

https://introspectivemarketresearch.com/reports/functional-proteins-market/

https://introspectivemarketresearch.com/reports/biodegradable-plastics-market/

Buy the Latest Version of this Report @

https://introspectivemarketresearch.com/checkout/?user=1&_sid=16460

Contact us:
Introspective Market Research
3001 S King Drive,
Chicago, Illinois
60616 USA
Ph no: +1 773 382 1049
Email: sales@introspectivemarketresearch.com

About us:
Introspective Market Research (introspectivemarketresearch.com) is a visionary research consulting firm dedicated to assist our clients grow and have a successful impact on the market. Our team at IMR is ready to assist our clients flourish their business by offering strategies to gain success and monopoly in their respective fields. We are a global market research company, specialized in using big data and advanced analytics to show the bigger picture of the market trends. We help our clients to think differently and build better tomorrow for all of us. We are a technology-driven research company, we analyze extremely large sets of data to discover deeper insights and provide conclusive consulting. We not only provide intelligence solutions, but we help our clients in how they can achieve their goals.

This release was published on openPR.